other material
confidence high
sentiment positive
materiality 0.85
Arvinas Phase 1 data: ARV-102 achieves >50% central and >90% peripheral LRRK2 degradation
ARVINAS, INC.
- ARV-102 well tolerated in healthy volunteers; no serious adverse events in SAD (completed) or MAD (ongoing) cohorts.
- At single dose ≥60 mg and repeated ≥20 mg: >90% LRRK2 reduction in PBMCs and >50% in CSF.
- Median Tmax 6h, terminal half-life 73h; CSF exposure dose-dependent across SAD and MAD.
- Phase 1 trial in Parkinson's disease patients initiated Q4 2024; initial patient data expected in 2025.